Institution - University of East Anglia
Researcher - Professor Colin Cooper
Grant award - £250,000
Duration - 2013-2016
Reference - PG12-14 Cooper

The project in a nutshell

Creating a new treatment of advanced/metastatic prostate cancer that uses tiny nanoparticles to deliver both a drug that weakens prostate cancer cells and standard chemotherapy drug docetaxel at the same time.

Why we funded it

Currently docetaxel is one of the last treatment options available for men with metastatic prostate cancer, but many develop resistance to the drug. The results of this research could lead to better results and longer survival for men with advanced prostate cancer.

Download digital versions of this research summary